

DR. JOHN MCCOY (Orcid ID : 0000-0003-1577-9910) DR. CARLOS WAMBIER (Orcid ID : 0000-0002-4636-4489) DR. SERGIO VANO-GALVAN (Orcid ID : 0000-0003-2773-7494) DR. PAULO MÜLLER RAMOS (Orcid ID : 0000-0002-1561-414X) DR. ANDY GOREN (Orcid ID : 0000-0002-8190-2289)

Article type : Letter to Editor

5-Alpha-Reductase Inhibitors are Associated with Reduced Frequency of COVID-19 Symptoms in Males with Androgenetic Alopecia

John McCoy, PhD^{1*}, Flávio Adsuara Cadegiani, MD, PhD², Carlos Gustavo Wambier, MD, PhD³, Sabina Herrera, MD, PhD⁴, Sergio Vaño-Galván, MD, PhD⁵, Natasha Atanaskova Mesinkovska, MD, PhD⁶, Paulo Müller Ramos, MD⁷, Jerry Shapiro, MD⁸, Rodney Sinclair, MD, PhD⁹, Antonella Tosti, MD¹⁰, Andy Goren, MD¹.

¹Applied Biology, Inc. Irvine, CA, USA.

²Department of Clinical Endocrinology, Federal University of São Paulo Medical School, Sao Paulo, Brazil.

³Department of Dermatology, Alpert Medical School of Brown University, Providence, RI, USA.

⁴Infectious Diseases Unit, Ramón y Cajal Hospital, Madrid, Spain.

⁵Dermatology Department, Ramón y Cajal Hospital, Madrid, Spain.

⁶Department of Dermatology, University of Claifornia, Irvine, CA, USA.

⁷Department of Dermatology, São Paulo State University – UNESP, São Paulo, Brazil

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the <u>Version of Record</u>. Please cite this article as <u>doi: 10.1111/JDV.17021</u>

This article is protected by copyright. All rights reserved

⁸Ronald O. Perelman Department of Dermatology, New York University School of Medicine, NY, USA.

⁹Sinclair Dermatology, Melbourne, VIC, Australia.

¹⁰Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, FL.

*Corresponding author:

John McCoy, PhD Applied Biology, Inc. 17780 Fitch, Suite 192 Irvine, CA 92614 johnm@appliedbiology.com

Funding sources: None

Conflicts of Interest: None declared.

IRB approval status: The study was approved by an ethics committee and registered with clinicaltrials.gov (NCT04446429).

Manuscript word count: 544 words

References: 6

Figures: 1

Tables: 1

Keywords: COVID-19; SARS-CoV-2; androgen receptor; androgenetic alopecia; antiandrogen therapy; transmembrane protease serine 2; TMPRSS2; dutasteride; finasteride; 5-alpha reductase;

Abbreviations:

5ARi: 5-alpha reductase inhibitors AGA: Androgenetic alopecia

Disclosure Statements:

John McCoy, PhD: Dr. McCoy has nothing to disclose. Flávio Adsuara Cadegiani, MD, PhD: Dr. Cadegiani has nothing to disclose. Carlos Gustavo Wambier, MD, PhD: Dr. Wambier has nothing to disclose. Sabina Herrera, MD, PhD: Dr. Herrera has nothing to disclose. Sergio Vaño-Galván, MD, PhD: Dr. Vano-Galvan has nothing to disclose. Natasha Atanaskova Mesinkovska, MD, PhD: Dr. Mesinkovska has nothing to disclose. Paulo Müller Ramos, MD, PhD: Dr. Ramos has nothing to disclose. Jerry Shapiro, MD: Dr. Shapiro has nothing to disclose. Rodney Sinclair, MD, PhD: Dr. Sinclair has nothing to disclose. Antonella Tosti, MD: Dr. Tosti has nothing to disclose.

Dear Editor, We have previously reported that men with androgenetic alopecia (AGA) are more likely to present with severe COVID-19 symptoms, potentially implicating androgen sensitivity as a risk factor for COVID-19.¹⁻³ As such, we hypothesized that 5-alpha-reductase inhibitors (5ARi) may reduce the severity of COVID-19 disease. To test this hypothesis we conducted a retrospective cohort analysis on male subjects with laboratory confirmed SARS-CoV-2 infection. The subjects presented at one of five outpatient clinics (Corpometria Institute Brasilia, Brazil) from June 15 to July 28, 2020. At the time of visit, 29 clinical symptoms associated with SARS-CoV-2 infection were documented. For analysis, male subjects with AGA were selected. The frequency of clinical symptoms in males with AGA using 5ARis was compared to those not using 5ARis.

Among the men presenting at the clinic, 300 were positive for SARS-CoV-2. Of these, 65 had AGA but were not using 5ARis, and 48 had AGA and were taking a 5ARi for at least six months prior to the study. The only 5ARi used in this cohort was dutasteride (0.5 mg) for the treatment of AGA. Propensity score matching analysis was performed on the 65 men in the AGA group not using 5ARis to produce a comparator to the 5ARi group (Area under the ROC curve = 0.548). The baseline characteristics of the matched study groups are displayed in **Table I**. The Fisher exact test was used to compare the proportions of clinical symptoms between COVID-19 patients with AGA using 5ARis and not using 5ARis. XLSTAT version 2020.3.1.1008 (Addinsoft, Inc.) was used to perform all statistical analysis.

A statistically significant (p<0.05) reduction in the frequency of 20 of the 29 clinical symptoms was observed in males with AGA using 5ARis compared to males with AGA not using 5ARis (**Figure I**); 5 of the symptoms were indistinguishable (p=1.00) because there were zero or close to zero occurrences in both groups. The largest percent reductions were found in the frequency of anosmia (73%), ageusia (63%), headache (42%), and dry cough (56%).

Men infected with SARS-CoV-2 have an increased risk of severe COVID-19 disease compared to women.⁴ A multitude of factors may contribute to this gender disparity,⁴ however, evidence is mounting^{1-3, 5} to support that androgens, the defining male hormones, may be implicated in COVID-19 disease severity. Androgens are both circulating and produced in tissue. Elevated tissue DHT is implicated in AGA, benign prostatic hyperplasia, and prostate cancer. In a previous communication, we reported that in a cohort of 122 hospitalized COVID-19 male patients, 79% suffered from AGA.¹ Similarly, Montopoli et al.,⁵ observed that men utilizing androgen depravation therapy for prostate cancer were less likely to suffer severe COVID-19 disease.

Here we demonstrate that men using the 5ARis, commonly used to treat AGA and benign prosthetic hyperplasia, display drastically reduced symptoms of COVID-19 disease in an outpatient setting. It is still unknown if treatment with 5ARis after SARS-CoV-2 infection will be beneficial to male patients. 5ARis, for example, dutasteride, may require days or weeks to lower DHT significantly to produce a therapeutic effect.⁶ These questions have encouraged a larger interventional study of anti-androgens in COVID-19 patients. We are currently conducting a randomized, double-blinded, placebo controlled interventional study with 5ARis (dutasteride) as well as a novel anti-androgen (proxalutamide) in the treatment of COVID-19 (NCT04446429).



1. Wambier CG, Vaño-Galván S, McCoy J, et al. Androgenetic Alopecia Present in the Majority of Hospitalized COVID-19 Patients - the "Gabrin sign" [published online ahead of print, 2020 May 21]. *J Am Acad Dermatol*. 2020;S0190-9622(20)30948-8. doi:10.1016/j.jaad.2020.05.079

2. Goren A, Vaño-Galván S, Wambier CG, et al. A preliminary observation: Male pattern hair loss among hospitalized COVID-19 patients in Spain - A potential clue to the role of androgens in COVID-19 severity. *J Cosmet Dermatol*. 2020;19(7):1545-1547. doi:10.1111/jocd.13443

3. Wambier CG, Vaño-Galván S, McCoy J, Pai S, Dhurat R, Goren A, Androgenetic alopecia in COVID-19: compared to age-matched epidemiologic studies and hospital outcomes with or without the Gabrin sign. *J Am Acad Dermatol*. 2020, doi: https://doi.org/10.1016/j.jaad.2020.07.099.

4. Gebhard C, Regitz-Zagrosek V, Neuhauser HK, Morgan R, Klein SL. Impact of sex and gender on COVID-19 outcomes in Europe. *Biol Sex Differ*. 2020;11(1):29. Published 2020 May 25. doi:10.1186/s13293-020-00304-9

5. Montopoli M, Zumerle S, Vettor R, et al. Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study

(n=4532) [published online ahead of print, 2020 May 4]. Ann Oncol 2020; S0923-7534(20)39797-0. doi:10.1016/j.annonc.2020.04.479

 Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked Suppression of Dihydrotestosterone in Men with Benign Prostatic Hyperplasia by Dutasteride, a Dual 5α-Reductase Inhibitor. J Clin Endocrinol Metab.
2004;89(5):2179-2184. doi:10.1210/jc.2003-030330

0		All SARS-C	All SARS-CoV-2 Positive	
()		5ARi (n=48)	no 5ARi (n=48)	
GROUP-DETERMING DATA, No.(%)	Androgenetic alopecia	48 (100)	48 (100)	
	Dutasteride use	48 (100)	0 (0)	
BASELINE DATA, No.(%)	Average Age, No.(SD)	45.6 (12)	45.7 (9)	
	BMI > 30 Kg/m2	9 (19)	8 (17)	
	Hypertension	12 (25)	11 (23)	
	Myocardial infarction	2 (4)	2 (4)	
	Stroke	0 (0)	0 (0)	
	Heart Failure	0 (0)	0 (0)	
	Lipid Disorder	24 (50)	17 (35)	
	Diabeties	9 (19)	5 (10)	
	Pre-diabeties	3 (6)	1 (2)	
	Obesity	9 (19)	8 (17)	
	Asthma	2 (4)	5 (10)	
	COPD	0 (0)	0 (0)	
	Cancer (current)	0 (0)	0 (0)	
	Cancer (previous)	0 (0)	1 (2)	
	Benign prostatic hyperplasia	5 (10)	2 (4)	
	Prostate Cancer	0 (0)	0 (0)	
	Chronic renal disease	0 (0)	0 (0)	
	Liver fibrosis/cirrhosis	0 (0)	0 (0)	
	Clinical depression	5 (10)	0 (0)	
	Anxiety	7 (15)	5 (10)	
	ADHD	6 (13)	4 (8)	
	Insomnia	5 (10)	2 (4)	

	Hypogonadism	3 (6)	4 (8)
	Hypothyroidism	2 (4)	1 (2)
	Autoimmune	0 (0)	0 (0)
	Other Diseases	0 (0)	0 (0)
MEDICATIONS Used, No. (%)			
ANTI-HYPERTENSIVES	Beta-blocker	4 (8)	3 (6)
	ECAi	5 (10)	4 (8)
-	Angiotensin II receptor blockers	9 (19)	9 (19)
	Loop diuretics	1 (2)	0 (0)
()	Thiazide diuretics	4 (8)	4 (8)
	Calcium channel blockers	6 (13)	4 (8)
	K-sparing diuretics	0 (0)	1 (2)
LIPID REDUCING AGENTS	Statins	23 (48)	14 (29)
	Others	2 (4)	2 (4)
ANTI-COAGULANTS	Aspirin	2 (4)	2 (4)
	Clopidogrel	0 (0)	0 (0)
	Xa factor inhibitors	3 (6)	0 (0)
ANTI-DIABETICS	Metformin	11 (23)	10 (21)
	GLP1R analogue	3 (6)	2 (4)
\geq	SGLT2 inhibitors	5 (10)	2 (4)
	DPP4 inhibitors	4 (8)	3 (6)
	Sylfonylureas	1 (2)	0 (0)
	Glitazone	0 (0)	1 (2)
	Acarbose	0 (0)	0 (0)
	Insulin	0 (0)	1 (2)
	Orlistat	2 (4)	5 (10)
HYPOTHYROIDISM	Levothyroxine	2 (4)	1 (2)
	Liothyronine	0 (0)	0 (0)
HYPOGONADISM	Testosterone	1 (2)	4 (8)
	Aromatase inhib. or SERMs	0 (0)	0 (0)
CENTRAL-ACTING DRUGS	Sedative	7 (15)	1 (2)
	SSRi	9 (19)	2 (4)
	Other antidepressants	2 (4)	3 (6)
	Benzodiazepines	2 (4)	0 (0)
	Atypical antipsychotics	0 (0)	0 (0)

	CNS stimulants	8 (17)	3 (6)
ANDROGENETIC ALOPECIA (others)	Finasteride	0 (0)	0 (0)
	Oral minoxidil	1 (2)	0 (0)
BPH (others)	Alpha-1 adren. blockers	3 (6)	2 (4)
ANDROGEN DEPRAVATION	GnRH analogues and inh., NSAA, others	0 (0)	0 (0)
ERECTILE DYSFUNCTION	Sildenafil, tadalafil, others	8 (17)	5 (10)
SUPPLEMENTATION	Omega-3	3 (6)	2 (4)
C	Vitamin D	9 (19)	5 (10)
	Zinc	1 (2)	1 (2)
	Biotin	5 (10)	2 (4)
	Vitamin C	2 (4)	3 (6)
VACCINES	BCG	48 (100)	48 (100)
	Influenza (in 2020)	7 (15)	7 (15)
	Pneumococcal (in 2020)	6 (13)	7 (15)
LIFESTYLE	Current Smoker (>2pk/week)	2 (4)	1 (2)
	Physical activity (>150 min/week)	22 (46)	11 (23)
σ			

Table I. Baseline Characteristics of Androgenetic Alopecia Men with COVID-19by Use and Nonuse of 5-alpha-reductase Inhibitors.

Shown are SARS-CoV-2 men with androgenetic alopecia using 5-alpha-reductase inhibitors (5ARi) compared to propensity score matched androgenetic alopecia men not using 5-alpha-reductase inhibitors (no 5ARi).

Autho



Author Mal

jdv_17021_f1.png

University Library



A gateway to Melbourne's research publications

Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

McCoy, J;Cadegiani, FA;Wambier, CG;Herrera, S;Vano-Galvan, S;Mesinkovska, NA;Ramos, PM;Shapiro, J;Sinclair, R;Tosti, A;Goren, A

Title:

5-alpha-reductase inhibitors are associated with reduced frequency of COVID-19 symptoms in males with androgenetic alopecia

Date:

2021-04

Citation:

McCoy, J., Cadegiani, F. A., Wambier, C. G., Herrera, S., Vano-Galvan, S., Mesinkovska, N. A., Ramos, P. M., Shapiro, J., Sinclair, R., Tosti, A. & Goren, A. (2021). 5-alpha-reductase inhibitors are associated with reduced frequency of COVID-19 symptoms in males with androgenetic alopecia. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 35 (4), pp.E243-E246. https://doi.org/10.1111/jdv.17021.

Persistent Link:

http://hdl.handle.net/11343/278525